SCHEMBL2548075

SCHEMBL2548075

COc1cc(F)c(N(C(=O)O)C(C)(C)C)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
HDAC1 Q13547 1/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 2/20 0.36
USP2 O75604 1/20 0.36
CYP3A4 P08684 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
ABCG2 Q9UNQ0 2/20 0.36
ALOX5 P09917 2/20 0.35
STAT3 P40763 2/20 0.35
NFE2L2 Q16236 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
PTPN1 P18031 1/20 0.35
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2548460 0.73 LMNA (0.43) LMNACYP3A4HTTNFE2L2MEN1
SCHEMBL7657146 0.71 MEN1 (0.39) CYP3A4SMN1; SMN2ALOX5MEN1MAPT
SCHEMBL3273001 0.70 GPR35 (0.31) AKR1C3AKR1C2HDAC1LMNANFE2L2
SCHEMBL18170324 0.69 MAPK1 (0.51) MAOALMNAMAPK1USP2CYP3A4
SCHEMBL12470369 0.68 MEN1 (0.38) AKR1C3AKR1C2HDAC1LMNAMAPK1
SCHEMBL7412320 0.67 HTT (0.43) AKR1C3AKR1C2LMNASMN1; SMN2HTT
SCHEMBL14909257 0.67 PIK3CA (0.35) HDAC1FFAR1
SCHEMBL2117365 0.66 SMN1; SMN2 (0.47) SMN1; SMN2HTTRAB9ANFE2L2GAA
SCHEMBL13235628 0.66 KMT2A (0.41) LMNAMAPK1USP2CYP3A4SMN1; SMN2
SCHEMBL16018019 0.66 TAAR1 (0.39) MAOAAKR1C3AKR1C2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB MAOA 3136/4885AKR1C3 88/4885AKR1C2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.